Hyperchloremic metabolic acidosis following resuscitation of shock.

50 mg rt-PA in reducing bleeding complications. Without accurate data of the bleeding complications in PTE thrombolytic therapy in China, we are currently unable to provide AR% for the Chinese population. Inspired by Dr Pena’s calculation, we performed additional analyses of the relative risk (RR) (I 50 mg/I 100 mg, the ratio of the bleeding incidences of the 50-mg rt-PA and 100-mg rt-PA groups), the absolute risk reduction (ARR) (I 100 mg 2 I 50 mg , the difference between the bleeding incidences of the 100-mg rt-PA and 50-mg rt-PA groups), and the number of patients needed to treated (NNT) (the number of patients needing to be treated with 50 mg rt-PA to reduce one bleeding incidence, 3 which is the reciprocal of the absolute risk difference, or 1/ARR(1/[I 100 mg 2 I 50 mg])( Table 1 ). In our study, the overall AR% is 47% and NNT is seven, indicating that seven patients need to be treated with 50 mg rt-PA to prevent one patient from bleeding complications. Importantly, the degree of benefi ts differs among patients with different body weights. AR% is relatively lower (26%) and NNT is higher (20) in patients with body weight  75 kg, AR% is increased (33%) and NNT is decreased (eight) in patients with body weight of 65 to 74 kg, and the AR% is highest (63%) and NNT is lowest (four) in patients with body weight , 65 kg. The similar trend is also observed in patients with different BMIs: the AR% is largest and NNT is smallest in patients with the lowest BMI. These data suggest that patients with PTE with lower body weight or BMI will benefi t more with 50 mg rt-PA treatment than patients with higher body weight or BMI. Finally, we thank Dr Pena again for his evaluation of our study. We look forward to more studies that validate our data in terms of therapeutic effi cacy and bleeding complication reduction.